vs
NEOGEN CORP（NEOG）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是Alpha Teknova, Inc.的22.5倍（$224.7M vs $10.0M）。NEOGEN CORP净利率更高（-7.1% vs -47.7%，领先40.6%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -2.8%）。NEOGEN CORP自由现金流更多（$7.8M vs $-810.0K）。过去两年Alpha Teknova, Inc.的营收复合增速更高（3.7% vs -0.9%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
NEOG vs TKNO — 直观对比
营收规模更大
NEOG
是对方的22.5倍
$10.0M
营收增速更快
TKNO
高出10.6%
-2.8%
净利率更高
NEOG
高出40.6%
-47.7%
自由现金流更多
NEOG
多$8.6M
$-810.0K
两年增速更快
TKNO
近两年复合增速
-0.9%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $10.0M |
| 净利润 | $-15.9M | $-4.8M |
| 毛利率 | 47.5% | 32.5% |
| 营业利润率 | -2.4% | -46.2% |
| 净利率 | -7.1% | -47.7% |
| 营收同比 | -2.8% | 7.8% |
| 净利润同比 | 96.5% | 16.8% |
| 每股收益（稀释后） | $-0.07 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOGTKNO
| Q4 25 | $224.7M | $10.0M | ||
| Q3 25 | $209.2M | $10.5M | ||
| Q2 25 | $225.4M | $10.3M | ||
| Q1 25 | $221.0M | $9.8M | ||
| Q4 24 | $231.3M | $9.3M | ||
| Q3 24 | $217.0M | $9.6M | ||
| Q2 24 | $236.8M | $9.6M | ||
| Q1 24 | $228.8M | $9.3M |
净利润NEOGTKNO
| Q4 25 | $-15.9M | $-4.8M | ||
| Q3 25 | $36.3M | $-4.3M | ||
| Q2 25 | $-612.3M | $-3.6M | ||
| Q1 25 | $-10.9M | $-4.6M | ||
| Q4 24 | $-456.3M | $-5.7M | ||
| Q3 24 | $-12.6M | $-7.6M | ||
| Q2 24 | $-5.4M | $-5.4M | ||
| Q1 24 | $-2.0M | $-8.1M |
毛利率NEOGTKNO
| Q4 25 | 47.5% | 32.5% | ||
| Q3 25 | 45.4% | 30.7% | ||
| Q2 25 | 41.2% | 38.7% | ||
| Q1 25 | 49.9% | 30.7% | ||
| Q4 24 | 49.0% | 23.0% | ||
| Q3 24 | 48.4% | 0.9% | ||
| Q2 24 | 47.9% | 29.2% | ||
| Q1 24 | 51.1% | 23.8% |
营业利润率NEOGTKNO
| Q4 25 | -2.4% | -46.2% | ||
| Q3 25 | -7.7% | -38.4% | ||
| Q2 25 | -271.1% | -32.9% | ||
| Q1 25 | 2.4% | -50.7% | ||
| Q4 24 | -197.8% | -60.7% | ||
| Q3 24 | 1.0% | -77.6% | ||
| Q2 24 | 5.5% | -53.0% | ||
| Q1 24 | 5.3% | -86.0% |
净利率NEOGTKNO
| Q4 25 | -7.1% | -47.7% | ||
| Q3 25 | 17.4% | -41.0% | ||
| Q2 25 | -271.6% | -34.7% | ||
| Q1 25 | -4.9% | -47.4% | ||
| Q4 24 | -197.3% | -61.7% | ||
| Q3 24 | -5.8% | -79.0% | ||
| Q2 24 | -2.3% | -55.8% | ||
| Q1 24 | -0.9% | -87.2% |
每股收益（稀释后）NEOGTKNO
| Q4 25 | $-0.07 | $-0.08 | ||
| Q3 25 | $0.17 | $-0.08 | ||
| Q2 25 | $-2.82 | $-0.07 | ||
| Q1 25 | $-0.05 | $-0.09 | ||
| Q4 24 | $-2.10 | $-0.09 | ||
| Q3 24 | $-0.06 | $-0.15 | ||
| Q2 24 | $-0.02 | $-0.13 | ||
| Q1 24 | $-0.01 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $2.1B | $68.8M |
| 总资产 | $3.4B | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资NEOGTKNO
| Q4 25 | $145.3M | $21.3M | ||
| Q3 25 | $138.9M | $22.1M | ||
| Q2 25 | $129.0M | $24.0M | ||
| Q1 25 | $127.7M | $26.3M | ||
| Q4 24 | $140.2M | $30.4M | ||
| Q3 24 | $120.5M | $31.7M | ||
| Q2 24 | $170.9M | $18.6M | ||
| Q1 24 | $168.4M | $21.6M |
总债务NEOGTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益NEOGTKNO
| Q4 25 | $2.1B | $68.8M | ||
| Q3 25 | $2.1B | $72.7M | ||
| Q2 25 | $2.1B | $76.1M | ||
| Q1 25 | $2.7B | $78.6M | ||
| Q4 24 | $2.7B | $82.4M | ||
| Q3 24 | $3.1B | $87.3M | ||
| Q2 24 | $3.1B | $78.9M | ||
| Q1 24 | $3.1B | $83.4M |
总资产NEOGTKNO
| Q4 25 | $3.4B | $103.6M | ||
| Q3 25 | $3.4B | $107.6M | ||
| Q2 25 | $3.4B | $110.5M | ||
| Q1 25 | $4.0B | $114.0M | ||
| Q4 24 | $4.1B | $118.8M | ||
| Q3 24 | $4.5B | $124.1M | ||
| Q2 24 | $4.5B | $115.4M | ||
| Q1 24 | $4.6B | $120.8M |
负债/权益比NEOGTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $7.8M | $-810.0K |
| 自由现金流率自由现金流/营收 | 3.5% | -8.1% |
| 资本支出强度资本支出/营收 | 5.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流NEOGTKNO
| Q4 25 | $19.4M | $-462.0K | ||
| Q3 25 | $10.9M | $-2.0M | ||
| Q2 25 | $16.4M | $-2.1M | ||
| Q1 25 | $19.5M | $-4.1M | ||
| Q4 24 | $40.3M | $-936.0K | ||
| Q3 24 | $-17.9M | $-2.1M | ||
| Q2 24 | $26.7M | $-2.8M | ||
| Q1 24 | $-30.2M | $-6.6M |
自由现金流NEOGTKNO
| Q4 25 | $7.8M | $-810.0K | ||
| Q3 25 | $-13.1M | $-2.4M | ||
| Q2 25 | $349.0K | $-2.3M | ||
| Q1 25 | $-13.4M | $-4.3M | ||
| Q4 24 | $23.1M | $-1.5M | ||
| Q3 24 | $-56.3M | $-2.4M | ||
| Q2 24 | $2.5M | $-3.0M | ||
| Q1 24 | $-62.3M | $-6.7M |
自由现金流率NEOGTKNO
| Q4 25 | 3.5% | -8.1% | ||
| Q3 25 | -6.3% | -22.6% | ||
| Q2 25 | 0.2% | -22.4% | ||
| Q1 25 | -6.1% | -44.0% | ||
| Q4 24 | 10.0% | -16.2% | ||
| Q3 24 | -26.0% | -25.0% | ||
| Q2 24 | 1.1% | -30.7% | ||
| Q1 24 | -27.2% | -71.8% |
资本支出强度NEOGTKNO
| Q4 25 | 5.2% | 3.5% | ||
| Q3 25 | 11.5% | 3.7% | ||
| Q2 25 | 7.1% | 2.0% | ||
| Q1 25 | 14.9% | 2.1% | ||
| Q4 24 | 7.4% | 6.1% | ||
| Q3 24 | 17.7% | 3.5% | ||
| Q2 24 | 10.2% | 1.2% | ||
| Q1 24 | 14.0% | 1.2% |
现金转化率NEOGTKNO
| Q4 25 | — | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
